Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Core Insights - Phathom Pharmaceuticals, Inc. clarified that a Schedule 13D filing by Frazier Life Sciences will include administrative changes to its reporting approach without indicating a reduction in ownership position by any Frazier fund or individual in Phathom [1] - The differences in the breakout of holdings between funds and individuals are attributed solely to clarifying changes in Frazier's reporting approach, not due to any sale of shares [2] Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), which is marketed in the U.S. under the brand VOQUEZNA® for various gastrointestinal conditions [3]